Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure- based virtual screening

被引:27
|
作者
Atatreh, Noor [1 ]
Ghattas, Mohammad A. [1 ]
Bardaweel, Sanaa K. [2 ]
Al Rawashdeh, Sara [1 ]
Al Sorkhy, Mohammad [1 ]
机构
[1] Al Ain Univ Sci & Technol, Dept Pharmaceut Sci, Coll Pharm, Al Ain, U Arab Emirates
[2] Univ Jordan, Dept Pharmaceut Sci, Sch Pharm, Amman 11942, Jordan
来源
关键词
protein-protein interaction; virtual screening; Mdm2; p53; anticancer; docking; pharmacophore; ELISA; P53-MDM2; INTERACTION; P53; PATHWAY; CANCER; DISCOVERY; DESIGN; POTENT;
D O I
10.2147/DDDT.S182444
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: The tumor suppressor protein p53 plays an important role in preventing tumor formation and progression through its involvement in cell division control and initiation of apoptosis. Mdm2 protein controls the activity of p53 protein through working as ubiquitin E3 ligase promoting p53 degradation through the proteasome degradation pathway. Inhibitors for Mdm2-p53 interaction have restored the activity of p53 protein and induced cancer fighting properties in the cell. Purpose: The objective of this study is to use computer-aided drug discovery techniques to search for new Mdm2-p53 interaction inhibitors. Methods: A set of pharmacophoric features were created based on a standard Mdm , inhibitor and this was used to screen a commercial drug-like ligand library; then potential inhibitors were docked and ranked in a multi-step protocol using GLIDE. Top ranked ligands from docking were evaluated for their inhibition activity of Mdm2-p53 interaction using ELISA testing. Results: Several compounds showed inhibition activity at the submicromolar level, which is comparable to the standard inhibitor Nutlin-3a. Furthermore, the discovered inhibitors were evaluated for their anticancer activities against different breast cancer cell lines, and they showed an interesting inhibition pattern. Conclusion: The reported inhibitors can represent a starting point for further SAR studies in the future and can help in the discovery of new anticancer agents.
引用
收藏
页码:3741 / 3752
页数:12
相关论文
共 50 条
  • [1] Structure-Based Design of Novel Inhibitors of the MDM2-p53 Interaction
    Rew, Yosup
    Sun, Daqing
    De Turiso, Felix Gonzalez-Lopez
    Bartberger, Michael D.
    Beck, Hilary P.
    Canon, Jude
    Chen, Ada
    Chow, David
    Deignan, Jeffrey
    Fox, Brian M.
    Gustin, Darin
    Huang, Xin
    Jiang, Min
    Jiao, Xianyun
    Jin, Lixia
    Kayser, Frank
    Kopecky, David J.
    Li, Yihong
    Lo, Mei-Chu
    Long, Alexander M.
    Michelsen, Klaus
    Oliner, Jonathan D.
    Osgood, Tao
    Ragains, Mark
    Saiki, Anne Y.
    Schneider, Steve
    Toteva, Maria
    Yakowec, Peter
    Yan, Xuelei
    Ye, Qiuping
    Yu, Dongyin
    Zhao, Xiaoning
    Zhou, Jing
    Medina, Julio C.
    Olson, Steven H.
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (11) : 4936 - 4954
  • [2] Inhibitors of the MDM2-p53 interaction as anticancer drugs
    Hardcastle, Ian R.
    DRUGS OF THE FUTURE, 2007, 32 (10) : 883 - 896
  • [3] The MDM2-p53 interaction
    Moll, UM
    Petrenko, O
    MOLECULAR CANCER RESEARCH, 2003, 1 (14) : 1001 - 1008
  • [4] Identification of novel inhibitors of p53-MDM2 interaction facilitated by pharmacophore-based virtual screening combining molecular docking strategy
    Wang, Weisi
    Zhu, Xiaolei
    Hong, Xueqin
    Zheng, Lin
    Zhu, Hong
    Hu, Yongzhou
    MEDCHEMCOMM, 2013, 4 (02) : 411 - 416
  • [5] MEDI 92-Discovery of potent small molecule inhibitors of the MDM2-p53 interaction through pharmacophore-based and structure-based database screening
    Lu, Yipin
    Nilolovska-Coleska, Zaneta
    Qiu, Su
    Kumar, Sanjeev
    Gao, Wei
    Fang, Xueliang
    Qin, Dongguang
    Wang, Shaomeng
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
  • [6] Structure-based de novo design of novel inhibitors of the MDM2-p53 interaction
    Sun, Daqing
    Rew, Yosup
    De Turiso, Felix Gonzalez Lopez
    Bartberger, Michael D.
    Beck, Hilary P.
    Canon, Jude
    Chen, Ada
    Chow, David
    Deignan, Jeffrey
    Fox, Brian M.
    Huang, Xin
    Jiang, Min
    Jiao, Xianyun
    Jin, Lixia
    Kopecky, David J.
    Li, Yihong
    Lo, Mei-Chu
    Long, Alexander M.
    Michelsen, Klaus
    Oliner, Jonathan D.
    Osgood, Tao
    Saiki, Anne Y.
    Schneider, Steve
    Yakowec, Peter
    Yan, Xuelei
    Ye, Qiuping
    Yu, Dongyin
    Zhao, Xiaoning
    Zhou, Jing
    Olson, Steven H.
    Medina, Julio C.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [7] Selective and potent morpholinone inhibitors of the MDM2-p53 interaction
    Gonzalez, Ana Z.
    Eksterowics, John
    Beck, Hilary P.
    Canon, Jude
    Chen, Ada
    Chow, David
    Duquette, Jason
    Fox, Brian M.
    Fu, Jiasheng
    Houze, Jonathan
    Jin, Lixia
    Li, Yihong
    Li, Zhihong
    Lo, Mei-Chu
    Long, Alexander M.
    McGee, Lawrence R.
    McIntosh, Joel
    Oliner, Jonathan D.
    Osgood, Tao
    Rew, Yosup
    Saiki, Anne Y.
    Shaffer, Paul
    Wortman, Sarah
    Yakowek, Peter
    Yan, Xuelei
    Ye, Qiuping
    Yu, Dongyin
    Zhao, Xiaoning
    Zhou, Jing
    Olson, Steven H.
    Medina, Julio C.
    Sun, Daqing
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [8] Identification of equal affinity MDMX/MDM2-p53 interaction small molecule inhibitors
    Reed, Damon
    Mills, Nicholas
    Guy, R. Kip
    Dyer, Michael
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3404S - 3404S
  • [9] Isoindolinone based inhibitors of the MDM2-p53 protein-protein interaction
    Kemp, SJ
    Hardcastle, IR
    Ahmed, SU
    Atatreh, NA
    Barrett, P
    Endicott, JA
    Golding, BT
    Griffin, RJ
    Gruber, J
    Hutton, C
    Lunec, J
    Noble, MEM
    Reid, RJ
    Riedinger, C
    Smyth, LA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2735 - U2736
  • [10] Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
    Thayer, Kelly M.
    Beyer, George A.
    PLOS ONE, 2016, 11 (03):